<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180672</url>
  </required_header>
  <id_info>
    <org_study_id>14-010942</org_study_id>
    <secondary_id>R01HL120909</secondary_id>
    <nct_id>NCT02180672</nct_id>
  </id_info>
  <brief_title>Steroids for Pediatric Apnea Research in Kids</brief_title>
  <acronym>SPARK</acronym>
  <official_title>Utility of Nasal Steroids for Treatment of Childhood Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, randomized controlled trial will evaluate the use of nasal corticosteroids&#xD;
      for the treatment of the childhood obstructive sleep apnea syndrome (OSAS). Efficacy,&#xD;
      duration of action and side-effects will be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have suggested that Nasal corticosteroids (NCS) or leukotriene antagonists&#xD;
      may be effective in the treatment of childhood OSAS. However, these studies have been limited&#xD;
      by factors such as small size, lack of randomization and blinding, short-term follow-up,&#xD;
      involvement of children with only very mild OSAS, and/or lack of stratifying for the presence&#xD;
      of atopy. Therefore, investigators will plan a randomized controlled trial evaluating the&#xD;
      efficacy and safety of NCS vs placebo in children with mild to moderate OSAS. The overall&#xD;
      hypothesis is that NCS will be safe and efficacious in the treatment of mild to moderate&#xD;
      childhood OSAS, particularly in children with asthma/atopy, but will require ongoing&#xD;
      maintenance therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obstructive Apnea Hypopnea Index</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy measure to assess acute response to nasal steroids.&#xD;
Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.&#xD;
The obstructive apnea hypopnea index (OAHI) is the sum of obstructive apneas and hypopneas, and mixed apneas divided by the total hours of sleep. Hence, the unit used is events per hour. It ranges from 0 events per hour(meaning no obstructive apneas at all) until 400 events per hour approximately. Higher values indicate more severe obstructive sleep apnea or worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OAHI</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy measure to assess duration of response to nasal steroids.&#xD;
Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Obstruction Symptom Evaluation (NOSE)</measure>
    <time_frame>12 months</time_frame>
    <description>Nasal Obstruction Symptom Evaluation (NOSE) scale, a validated scale of nasal obstructive symptoms. The scales ranges from 0-100 with higher values indicating worse nasal obstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Epworth Sleepiness Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Epworth Sleepiness scale is a measure of sleepiness that ranges from 0-24, with higher values indicating sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL)</measure>
    <time_frame>12 month</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL), a well-validated, generic measure of global quality of life, in which scores range from 0 to 100, with higher scores indicating better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>12 months</time_frame>
    <description>Behavior Rating Inventory of Executive Function [BRIEF] Global Executive Composite T score, comprising summary measures of behavioral regulation and metacognition [with mean scores of 50 and standard deviation of 10, with higher scores indicating worse functioning]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Abbreviated Symptom Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>A parent-rated measure of symptoms of attention problems, yielding T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Purdue Peg Board</measure>
    <time_frame>12 months</time_frame>
    <description>The Purdue Peg Board is a widely used test of fine motor coordination, yields z-scores with a mean of 0 and a standard deviation of 1, with higher scores indicating better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Continuous Performance Test (CPT)</measure>
    <time_frame>12 months</time_frame>
    <description>The CPT is a performance measure of sustained attention that yields T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist</measure>
    <time_frame>12-Months</time_frame>
    <description>The Child Behavior Checklist (CBCL), is a widely used and validated caregiver-completed survey of behavior competencies that yields standardized, age-adjusted scores on internalizing, externalizing and attentional behavior difficulties81, 82. All scores are T scores with a mean of 50 and standard deviation of 10 (higher scores indicate worse functioning).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Nasal steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Fluticasone</intervention_name>
    <description>One spray per nostril, per day.</description>
    <arm_group_label>Nasal steroids</arm_group_label>
    <other_name>NCS</other_name>
    <other_name>Nasal steroids</other_name>
    <other_name>Nasal corticosteroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One spray per nostril, per day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. 5-10 years of age.&#xD;
&#xD;
          2. Mild to moderate OSAS, defined as an obstructive apnea index of 1-20/hr of total sleep&#xD;
             time or obstructive apnea hypopnea index of 2-30/hr of total sleep time.&#xD;
&#xD;
          3. Parent-related symptoms of habitual snoring (&gt;3 nights per week)&#xD;
&#xD;
          4. No history of adenotonsillectomy.&#xD;
&#xD;
          5. Parental/guardian permission (informed consent) and if appropriate, child assent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Severe OSAS or significant hypoxemia or hypercapnia on polysomnography, such that&#xD;
             definitive treatment should not be delayed (AHI &gt; 30/hr, more than 2% total sleep time&#xD;
             with arterial oxygen saturation (SpO2) &lt;90%, end-tidal carbon dioxide partial pressure&#xD;
             (PCO2) &gt; 60 mm Hg for &gt; 5 minutes, pathologic arrhythmias).&#xD;
&#xD;
          2. History of recurrent throat infections (as defined by the American Academy of&#xD;
             Otolaryngology-Head and Neck Surgery Clinical Practice Guidelines For Tonsillectomy&#xD;
             (7)) in the past few years as follows: &gt; 7 episodes in the past year or &gt; 5&#xD;
             episodes/year over the past 2 years or &gt; 3 episodes/year over the past 3 years.&#xD;
&#xD;
          3. Abnormalities on baseline safety screening tests, i.e., Dual Energy X-ray&#xD;
             Absorptiometry (DXA) scan showing spine or whole body bone mineral density &lt; -2.0&#xD;
             standard deviations using race specific curves with adjustment for height Z-score;&#xD;
             morning cortisol &lt; 3 µg/dl or morning adrenocorticotropic hormone (ACTH) &lt; 10 pg/ml;&#xD;
             or ophthalmologic exam demonstrating cataracts (except those with &lt; 2 mm anterior&#xD;
             polar cataracts), aphakia or other ocular abnormalities such as glaucoma, retinal&#xD;
             coloboma, intraocular inflammation or microphthalmia.&#xD;
&#xD;
          4. Failure to thrive (weight/height &lt; 5th percentile for age and gender), as this may be&#xD;
             secondary to OSAS.&#xD;
&#xD;
          5. Severe obesity (BMI z-score &gt; 3) as OSAS is likely to persist in these subjects.&#xD;
&#xD;
          6. Previous adenoidectomy unless adenoidal tissue has been documented to have regrown.&#xD;
&#xD;
          7. Previous tonsillectomy.&#xD;
&#xD;
          8. Continuous positive airway pressure (CPAP) therapy.&#xD;
&#xD;
          9. Any NCS use in the past 3 months or NCS use for &gt; 2 weeks in the past year.&#xD;
&#xD;
         10. Current immunotherapy or daily antihistamine use.&#xD;
&#xD;
         11. Recent (past month) nasal septum ulcers, surgery or trauma.&#xD;
&#xD;
         12. Other major illness other than asthma, such as craniofacial anomalies, endocrine or&#xD;
             neuromuscular disease, or past history of cancer. This includes children with&#xD;
             conditions that may be worsened by OSAS, such as hypertension or diabetes.&#xD;
&#xD;
         13. Current use of ketoconazole or other potent CYP3A4 inhibitors.&#xD;
&#xD;
         14. Families planning to move out of the area within the year.&#xD;
&#xD;
         15. Subjects who do not speak either English or Spanish well enough to complete the&#xD;
             validated neurobehavioral instruments.&#xD;
&#xD;
         16. Parents/guardians or subjects who, in the opinion of the Investigator, may be&#xD;
             non-compliant with study schedules or procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole L Marcus, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.research.chop.edu/research/clinical-research</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <results_first_submitted>December 1, 2020</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2021</results_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive sleep apnea syndrome</keyword>
  <keyword>OSA</keyword>
  <keyword>sleep apnea</keyword>
  <keyword>nasal steroids</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02180672/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02180672/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Screening: polysomnography, ophthalmologic exam, DXA scan. 75 children did not meet PSG inclusion criteria, 1 child had a coloboma, and 1 child had abnormal DXA scan.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nasal Steroids</title>
          <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nasal Steroids</title>
          <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.24" spread="2.17"/>
                    <measurement group_id="B2" value="8.10" spread="2.03"/>
                    <measurement group_id="B3" value="8.17" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OAHI</title>
          <description>Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.85" lower_limit="6.50" upper_limit="9.20"/>
                    <measurement group_id="B2" value="6.51" lower_limit="5.09" upper_limit="7.94"/>
                    <measurement group_id="B3" value="7.52" lower_limit="3.40" upper_limit="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Obstrction Symptoms Evaluation (NOSE)</title>
          <description>Nasal Obstruction Symptom Evaluation (NOSE) scale is a validated scale of nasal obstructive symptoms, modified by deleting the question about sleep and written in child-friendly language.</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.59" lower_limit="4.60" upper_limit="6.59"/>
                    <measurement group_id="B2" value="4.47" lower_limit="3.07" upper_limit="5.88"/>
                    <measurement group_id="B3" value="5.03" lower_limit="3.84" upper_limit="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Epworth Sleepiness Scale</title>
          <description>Epworth Sleepiness scale is a measure of sleepiness that ranges from 0-24, with higher values indicating sleepiness</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.09" lower_limit="8.09" upper_limit="10.1"/>
                    <measurement group_id="B2" value="7.58" lower_limit="5.54" upper_limit="9.63"/>
                    <measurement group_id="B3" value="8.34" lower_limit="6.82" upper_limit="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric Quality of Life (PedsQL)</title>
          <description>Pediatric Quality of Life Inventory (PedsQL) is a well-validated, generic measure of global quality of life in which scores range from 0 to 100, with higher scores indicating better quality of life</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.91" lower_limit="69.90" upper_limit="77.930"/>
                    <measurement group_id="B2" value="78.44" lower_limit="72.0" upper_limit="84.89"/>
                    <measurement group_id="B3" value="76.175" lower_limit="70.95" upper_limit="81.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Behavior Rating Inventory of Executive Function (BRIEF)</title>
          <description>Behavior Rating Inventory of Executive Function [BRIEF] Global Executive Composite T score, comprising summary measures of behavioral regulation and metacognition [with mean scores of 50 and standard deviation of 10, with higher scores indicating worse functioning]</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.86" lower_limit="47.95" upper_limit="53.77"/>
                    <measurement group_id="B2" value="47.11" lower_limit="42.52" upper_limit="51.70"/>
                    <measurement group_id="B3" value="48.985" lower_limit="45.235" upper_limit="52.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conners Abbreviated Symptom Questionnaire</title>
          <description>The Conners Abbreviated Symptom Questionnaire is a parent-rated measure of symptoms of attention problems, yielding T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning).</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.19" lower_limit="6.49" upper_limit="9.88"/>
                    <measurement group_id="B2" value="5.97" lower_limit="3.81" upper_limit="8.14"/>
                    <measurement group_id="B3" value="7.08" lower_limit="5.15" upper_limit="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conners Continuous Performance Test (CPT)</title>
          <description>The CPT is a performance measure of sustained attention that yields T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning)</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" lower_limit="52.83" upper_limit="56.77"/>
                    <measurement group_id="B2" value="56.1" lower_limit="52.65" upper_limit="59.55"/>
                    <measurement group_id="B3" value="55.45" lower_limit="52.74" upper_limit="58.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Purdue Peg Board</title>
          <description>The Purdue Peg Board is a widely used test of fine motor coordination, yields z-scores with a mean of 0 and a standard deviation of 1, with higher scores indicating better performance.</description>
          <population>The total number of analyzed is different than the total number of participants is due to participants withdrawing themselves from the study or being lost to follow up.</population>
          <units>z-Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="85"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.06" lower_limit="-1.35" upper_limit="-0.78"/>
                    <measurement group_id="B2" value="-1.39" lower_limit="-1.83" upper_limit="0.95"/>
                    <measurement group_id="B3" value="-1.225" lower_limit="-1.59" upper_limit="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Obstructive Apnea Hypopnea Index</title>
        <description>Efficacy measure to assess acute response to nasal steroids.&#xD;
Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.&#xD;
The obstructive apnea hypopnea index (OAHI) is the sum of obstructive apneas and hypopneas, and mixed apneas divided by the total hours of sleep. Hence, the unit used is events per hour. It ranges from 0 events per hour(meaning no obstructive apneas at all) until 400 events per hour approximately. Higher values indicate more severe obstructive sleep apnea or worse outcome.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Obstructive Apnea Hypopnea Index</title>
          <description>Efficacy measure to assess acute response to nasal steroids.&#xD;
Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.&#xD;
The obstructive apnea hypopnea index (OAHI) is the sum of obstructive apneas and hypopneas, and mixed apneas divided by the total hours of sleep. Hence, the unit used is events per hour. It ranges from 0 events per hour(meaning no obstructive apneas at all) until 400 events per hour approximately. Higher values indicate more severe obstructive sleep apnea or worse outcome.</description>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69" lower_limit="5.39" upper_limit="9.99"/>
                    <measurement group_id="O2" value="6.33" lower_limit="4.09" upper_limit="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OAHI</title>
        <description>Efficacy measure to assess duration of response to nasal steroids.&#xD;
Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.</description>
        <time_frame>12 months</time_frame>
        <population>The obstructive apnea hypopnea index (OAHI) is the sum of obstructive apneas and hypopneas, and mixed apneas divided by the total hours of sleep. Hence, the unit used is events per hour. It ranges from 0 events per hour(meaning no obstructive apneas at all) until 400 events per hour approximately. Higher values indicate more severe obstructive sleep apnea or worse outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>OAHI</title>
          <description>Efficacy measure to assess duration of response to nasal steroids.&#xD;
Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.</description>
          <population>The obstructive apnea hypopnea index (OAHI) is the sum of obstructive apneas and hypopneas, and mixed apneas divided by the total hours of sleep. Hence, the unit used is events per hour. It ranges from 0 events per hour(meaning no obstructive apneas at all) until 400 events per hour approximately. Higher values indicate more severe obstructive sleep apnea or worse outcome.</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" lower_limit="3.97" upper_limit="8.24"/>
                    <measurement group_id="O2" value="6.27" lower_limit="3.98" upper_limit="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Obstruction Symptom Evaluation (NOSE)</title>
        <description>Nasal Obstruction Symptom Evaluation (NOSE) scale, a validated scale of nasal obstructive symptoms. The scales ranges from 0-100 with higher values indicating worse nasal obstruction</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Obstruction Symptom Evaluation (NOSE)</title>
          <description>Nasal Obstruction Symptom Evaluation (NOSE) scale, a validated scale of nasal obstructive symptoms. The scales ranges from 0-100 with higher values indicating worse nasal obstruction</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" lower_limit="2.54" upper_limit="4.77"/>
                    <measurement group_id="O2" value="5.31" lower_limit="3.43" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Epworth Sleepiness Scale</title>
        <description>Epworth Sleepiness scale is a measure of sleepiness that ranges from 0-24, with higher values indicating sleepiness</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>The Epworth Sleepiness Scale</title>
          <description>Epworth Sleepiness scale is a measure of sleepiness that ranges from 0-24, with higher values indicating sleepiness</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" lower_limit="6.24" upper_limit="9.12"/>
                    <measurement group_id="O2" value="8.56" lower_limit="6.68" upper_limit="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pediatric Quality of Life Inventory (PedsQL)</title>
        <description>Pediatric Quality of Life Inventory (PedsQL), a well-validated, generic measure of global quality of life, in which scores range from 0 to 100, with higher scores indicating better quality of life</description>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Quality of Life Inventory (PedsQL)</title>
          <description>Pediatric Quality of Life Inventory (PedsQL), a well-validated, generic measure of global quality of life, in which scores range from 0 to 100, with higher scores indicating better quality of life</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.69" lower_limit="72.93" upper_limit="84.45"/>
                    <measurement group_id="O2" value="73.67" lower_limit="66.66" upper_limit="80.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Behavior Rating Inventory of Executive Function (BRIEF)</title>
        <description>Behavior Rating Inventory of Executive Function [BRIEF] Global Executive Composite T score, comprising summary measures of behavioral regulation and metacognition [with mean scores of 50 and standard deviation of 10, with higher scores indicating worse functioning]</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Behavior Rating Inventory of Executive Function (BRIEF)</title>
          <description>Behavior Rating Inventory of Executive Function [BRIEF] Global Executive Composite T score, comprising summary measures of behavioral regulation and metacognition [with mean scores of 50 and standard deviation of 10, with higher scores indicating worse functioning]</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.42" lower_limit="43.93" upper_limit="50.91"/>
                    <measurement group_id="O2" value="49.5" lower_limit="44.01" upper_limit="54.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conners Abbreviated Symptom Questionnaire</title>
        <description>A parent-rated measure of symptoms of attention problems, yielding T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Conners Abbreviated Symptom Questionnaire</title>
          <description>A parent-rated measure of symptoms of attention problems, yielding T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning).</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" lower_limit="3.73" upper_limit="7.52"/>
                    <measurement group_id="O2" value="6.50" lower_limit="3.84" upper_limit="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Purdue Peg Board</title>
        <description>The Purdue Peg Board is a widely used test of fine motor coordination, yields z-scores with a mean of 0 and a standard deviation of 1, with higher scores indicating better performance.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Purdue Peg Board</title>
          <description>The Purdue Peg Board is a widely used test of fine motor coordination, yields z-scores with a mean of 0 and a standard deviation of 1, with higher scores indicating better performance.</description>
          <units>z-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" lower_limit="-1.7" upper_limit="-0.54"/>
                    <measurement group_id="O2" value="-1.31" lower_limit="-1.79" upper_limit="-0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conners Continuous Performance Test (CPT)</title>
        <description>The CPT is a performance measure of sustained attention that yields T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Conners Continuous Performance Test (CPT)</title>
          <description>The CPT is a performance measure of sustained attention that yields T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning)</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.67" lower_limit="49.07" upper_limit="56.27"/>
                    <measurement group_id="O2" value="52.92" lower_limit="48.74" upper_limit="57.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Child Behavior Checklist</title>
        <description>The Child Behavior Checklist (CBCL), is a widely used and validated caregiver-completed survey of behavior competencies that yields standardized, age-adjusted scores on internalizing, externalizing and attentional behavior difficulties81, 82. All scores are T scores with a mean of 50 and standard deviation of 10 (higher scores indicate worse functioning).</description>
        <time_frame>12-Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroids</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Child Behavior Checklist</title>
          <description>The Child Behavior Checklist (CBCL), is a widely used and validated caregiver-completed survey of behavior competencies that yields standardized, age-adjusted scores on internalizing, externalizing and attentional behavior difficulties81, 82. All scores are T scores with a mean of 50 and standard deviation of 10 (higher scores indicate worse functioning).</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Internalizing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.92" lower_limit="47.01" upper_limit="52.83"/>
                    <measurement group_id="O2" value="51.94" lower_limit="47.46" upper_limit="56.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.89" lower_limit="48.45" upper_limit="55.34"/>
                    <measurement group_id="O2" value="52" lower_limit="47.34" upper_limit="56.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Behavior Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.45" lower_limit="48.47" upper_limit="54.43"/>
                    <measurement group_id="O2" value="51.19" lower_limit="45.99" upper_limit="56.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.13" lower_limit="53.47" upper_limit="56.79"/>
                    <measurement group_id="O2" value="57.38" lower_limit="54.15" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected monthly at telephone calls at months 2, 4, 5, 7, 8, 10 and 11, and during in-person visits at months 1, 3, 6, 9 and 12.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nasal Steroids</title>
          <description>Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).&#xD;
Nasal Fluticasone: One spray per nostril, per day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).&#xD;
Placebo: One spray per nostril, per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Ketotic Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Tract</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Illness</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other Infections</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Respiratory Tract (Including Asthma)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract (including cough)</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="86"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sleep Apnea Exacerbation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ignacio Tapia, MD, Principal Investigator, Associate Professor</name_or_title>
      <organization>The Children's Hospital of Philadelphia</organization>
      <phone>(267) 426-5842</phone>
      <email>tapia@chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

